These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8092158)

  • 21. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antiemetic prophylaxis after laparoscopic cholecystectomy: comparative study of dehydrobenzperidol, metoclopramide, ondansetron and placebo].
    Pertusa V; Bellver J; Marqués A; Onrubia X; Viñals MP; Sanmiguel G; Seller JM; Martínez-Carrasco C
    Rev Esp Anestesiol Reanim; 1996; 43(7):239-42. PubMed ID: 8966351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ondansetron--a new anesthesia relevant antiemetic?].
    Böhrer H; Bach A; Martin E
    Anaesthesiol Reanim; 1994; 19(1):11-3. PubMed ID: 8141957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
    Hernández García D; Lara Vila I; Caba Barrientos F; Ramos Curado P; Núñez García A; Echevarría Moreno M
    Rev Esp Anestesiol Reanim; 2007 Apr; 54(4):213-20. PubMed ID: 17518171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and economy of low-dose ondansetron.
    Walton SC; Koenig TJ
    Am J Health Syst Pharm; 1995 Mar; 52(5):546-7. PubMed ID: 7606564
    [No Abstract]   [Full Text] [Related]  

  • 27. [Metoclopramide and cisplatin].
    Grau JJ; Millá A; Cirera L; Estapé J
    Med Clin (Barc); 1983 Dec; 81(20):926. PubMed ID: 6686628
    [No Abstract]   [Full Text] [Related]  

  • 28. Right, wrong, and surrogate endpoints.
    Gelman S
    Anesthesiology; 1995 Apr; 82(4):1084-5. PubMed ID: 7717545
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness as a guide to pricing a new pharmaceutical product.
    Reekie WD; Buxton MJ
    S Afr Med J; 1994 Jul; 84(7):421-3. PubMed ID: 7709308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Right, wrong, and surrogate endpoints.
    Khalil S
    Anesthesiology; 1995 Apr; 82(4):1084-5. PubMed ID: 7717546
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter: Metoclopramide in parkinsonism.
    Tarsy D; Parkes JD; Marsden CD
    Lancet; 1975 May; 1(7918):1244-5. PubMed ID: 48872
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cost-effective treatment with ondansetron].
    Glaxo AS
    Tidsskr Nor Laegeforen; 1993 Aug; 113(20):2602. PubMed ID: 7639831
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of the pharmacoeconomic literature.
    Milne RJ
    Pharmacoeconomics; 1994 Oct; 6(4):337-45. PubMed ID: 10147470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New guidelines for ondansetron use prove cost-effective.
    Johnson MH; Gay CF; Moroney CE
    Oncol Nurs Forum; 1995 Jun; 22(5):851-2. PubMed ID: 7675694
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of cost containment on research and development.
    Motta GJ
    J Enterostomal Ther; 1986; 13(5):193-5. PubMed ID: 3093548
    [No Abstract]   [Full Text] [Related]  

  • 36. Value on the margin?
    Vermeulen LC
    Am J Health Syst Pharm; 2002 Mar; 59(6):527. PubMed ID: 11908244
    [No Abstract]   [Full Text] [Related]  

  • 37. Measuring and communicating the contributions of research.
    Faust RE; Stevenson RH
    Perspect Biol Med; 1978; 21(2):301-11. PubMed ID: 417292
    [No Abstract]   [Full Text] [Related]  

  • 38. Letter: Cost containment.
    Freeman RA
    J Med Educ; 1976 Feb; 51(2):157-8. PubMed ID: 814240
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug trials: allowing for cost.
    Lancet; 1977 Sep; 2(8038):595. PubMed ID: 71407
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness, not cost containment.
    Zbrozek AS
    Am J Hosp Pharm; 1994 Jun; 51(12):1569-71. PubMed ID: 8092158
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.